Clinical

Dataset Information

0

Preventive effect of shakuyaku-kanzo-to on neurotoxicity of FOLFOX plus bevacizumab for patients with metastatic colorectal cancer: a prospective phase II study


ABSTRACT: Interventions: Patients receive FOLFOX4 plus bevacizumab or modified FOLFOX6 plus bevacizumab and take shakuyaku-kanzo-to (7.5g/day) orally every day during FOLFOX plus bevacizumab treatment. Primary outcome(s): Neurotoxicity frequency of accumulation dose 500mg/m2 of oxaliplatin Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2617341 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2624861 | ecrin-mdr-crc
| 2619732 | ecrin-mdr-crc
| 2631410 | ecrin-mdr-crc
2013-01-03 | E-GEOD-19860 | biostudies-arrayexpress
| 2617692 | ecrin-mdr-crc
| PRJNA578152 | ENA
2019-12-19 | GSE142308 | GEO
2023-04-19 | GSE208103 | GEO
2024-08-26 | GSE275628 | GEO
| 2628289 | ecrin-mdr-crc